Effects of compound Caoshi silkworm granules on stable COPD patients and their relationship with gut microbiota A randomized controlled trial
Effects of compound Caoshi silkworm granules on stable COPD patients and their relationship with gut microbiota A randomized controlled trial
复制标题
DOI：
10.1097/md.0000000000020511
复制
发表时间：
2020-05-29
期刊：
影响因子：
1.6
通讯作者：
Xu, Bin
中科院分区：
文献类型：
--
作者：
Hu, Yibing;Shi, Qinghuan;Xu, Bin
背景与目的：慢性阻塞性肺疾病(COPD)患者常出现反复急性加重。这些患者，特别是那些病情稳定的COPD患者，需要有效的干预措施来治疗病情恶化。本研究旨在评价复方草食蚕丝颗粒治疗缓解期慢性阻塞性肺疾病的疗效，并探讨其可能的作用机制。方法：在浙江大学金华医院进行随机对照试验。符合稳定期COPD标准的患者纳入本研究。将40例患者随机分为常规治疗组(A组，n=20)和常规治疗+CCSGs组(B组，n=20)。疗程均为3个月。于第0天采集所有患者的粪便样本，用16S rRNA测序分析肠道微生物区系。分别于0个月和3个月进行圣乔治呼吸问卷(SGRQ)评分和肺功能评定。结果：COPD稳定期患者与健康人群肠道微生物区系组成不同。与RT组相比，RT+CCSGs组的SGRQ评分有所改善。两组在用力呼气量-1秒、用力肺活量和用力呼气量-1秒/用力肺活量方面没有差异。此外，SGRQ得分前10位的患者(N组)的肠道微生物区系丰度与SGRQ得分最低的10位患者(T组)的肠道微生物区系丰度不同。结论：CCSGs对缓解期COPD患者治疗3个月后的症状改善有一定的疗效。潜在的潜在机制可能是由于患者之间肠道微生物区系的差异。然而，还需要更多的研究来证实这一结论。
Background and purpose: Patients with chronic obstructive pulmonary disease (COPD) usually experience recurrent acute exacerbations. These patients, especially those with stable COPD, require an effective intervention for treating exacerbations. This study aimed to evaluate the efficacy of Compound Caoshi silkworm granules (CCSGs) in stable COPD patients and to investigate their potential mechanism. Methods: A randomized controlled trial was performed at Jinhua Hospital, Zhejiang University. Patients were enrolled in this study if they met the criterion of stable COPD. A total of 40 patients were randomly divided into the following 2 groups: Group A (n = 20, routine treatment (RT) group) and Group B (n = 20, RT plus CCSGs [RT plus CCSGs] group). The duration of treatment was 3 months. Stool samples were collected from all patients on day 0 and the gut microbiota was analyzed using 16s rRNA sequencing. The St. George's Respiratory Questionnaire (SGRQ) scores and lung function were assessed at month 0 and month 3. Results: The components of gut microbiota differed between stable COPD patients and the healthy population. The RT plus CCSGs group showed improved SGRQ scores compared to the RT group. There was no difference in forced expiratory volume-one second, forced vital capacity, and forced expiratory volume-one second/forced vital capacity between the two groups. Furthermore, the abundance of gut microbiota in patients with the top 10 SGRQ scores (Group N) differed from the abundance of gut microbiota in those with the lowest 10 SGRQ scores (Group T). Conclusion: CCSGs have beneficial effects in the improvement of symptoms in stable COPD patients over a 3-month treatment period. The potential underlying mechanism may be attributable to the difference in gut microbiota among patients. However, more research is needed to confirm this conclusion.